ETBI Stock Overview
A development stage company, develops novel formulations of natural compounds and pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eastgate Biotech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0045 |
| 52 Week High | US$0.009 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | 66.67% |
| 5 Year Change | -35.71% |
| Change since IPO | -98.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| ETBI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 0.6% |
| 1Y | n/a | 7.9% | 23.7% |
Return vs Industry: Insufficient data to determine how ETBI performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ETBI performed against the US Market.
Price Volatility
| ETBI volatility | |
|---|---|
| ETBI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ETBI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ETBI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Rose Perri | www.EastGateBiotech.com |
Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil.
Eastgate Biotech Corp. Fundamentals Summary
| ETBI fundamental statistics | |
|---|---|
| Market cap | US$4.76m |
| Earnings (TTM) | -US$3.82m |
| Revenue (TTM) | US$137.64k |
0.0x
P/S Ratio0.0x
P/E RatioIs ETBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETBI income statement (TTM) | |
|---|---|
| Revenue | US$137.64k |
| Cost of Revenue | US$149.28k |
| Gross Profit | -US$11.64k |
| Other Expenses | US$3.81m |
| Earnings | -US$3.82m |
Last Reported Earnings
Sep 30, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ETBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 11:04 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2017/09/30 |
| Annual Earnings | 2016/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eastgate Biotech Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|